Here are the DEF 14A proxy statements from Terra Innovatum Global N.V. (NKLR) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow NKLR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NKLR filings page.
Terra Innovatum Global N.V. (NKLR) seeks shareholder votes at its November 16, 2026 annual meeting on 2025 accounts matters, director appointments, director equity awards, a revised remuneration policy, a share-buyback authorization and withdrawal of KPMG’s Dutch audit engagement for 2025. The Board recommends voting “FOR” each voting item.
Proposed director awards are capped at 2,000,000 ordinary shares or rights to acquire ordinary shares for November 16, 2026 through December 31, 2029, with annual increases of up to 250,000; approval would not expand the existing plan reserve. The proposed policy sets executive short-term incentives at a 100%-of-base-salary target, with maximums of 100% of base salary if cash-settled or up to 250% if equity-settled, and permits a future long-term plan subject to approvals. The proposed 18-month buyback is limited to 10% of issued capital and a price no higher than 110% of the average closing price on the five trading days preceding agreement; the company says it does not currently intend to exercise the authorization.
KPMG’s appointment as independent registered public accounting firm ended October 12, 2026, and MaloneBailey was engaged October 23 for 2026. Terra Innovatum says it qualifies as a small legal entity, so its Dutch statutory audit for 2025 is not required. Internal-control material weaknesses remain unremediated; MaloneBailey’s report for the period ended April 29, 2025 expressed substantial doubt about the company’s ability to continue as a going concern.